Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | GPX4 | P36969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29973846 | 0.89 | ALDH1A1 (0.47) | ALDH1A1NPC1MAPTHTTRAB9A | |
| SCHEMBL30608789 | 0.82 | ALDH1A1 (0.69) | ALDH1A1 | |
| SCHEMBL28907163 | 0.78 | CYP19A1 (0.34) | ALDH1A1CYP19A1 | |
| SCHEMBL25938254 | 0.67 | CYP1A2 (0.56) | ALDH1A1 | |
| SCHEMBL3031437 | 0.65 | ALDH1A1 (1.00) | ALDH1A1CYP19A1 | |
| SCHEMBL19036305 | 0.56 | GPX4 (0.71) | ALDH1A1NPC1MAPTHTTRAB9A | |
| SCHEMBL19036316 | 0.55 | GPX4 (0.76) | ALDH1A1NPC1MAPTHTTRAB9A | |
| SCHEMBL9078420 | 0.53 | CYP19A1 (0.69) | ALDH1A1NPC1RAB9AKDM4ECYP19A1 | |
| SCHEMBL9078999 | 0.53 | CYP19A1 (0.51) | NPC1MAPTRAB9AATMTDP1 | |
| SCHEMBL1179218 | 0.53 | CYP4Z1 (0.55) | ALDH1A1MAPTKDM4EFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255917-A1 | COMPOSITION COMPRISING CHICORY ROOT AND PEA CELL WALL FIBER FOR TREATING BRACHYSPIRA INFECTIONS | COSUCRA GROUPE WARCOING S.A. (BE) | 2025-08-14 | — | — | US | claimed |
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | claimed |
| US-12290545-B2 | Composition comprising chicory root and pea cell wall fiber for treating Brachyspira infections | COSUCRA GROUPE WARCOING S.A. (BE) | 2025-05-06 | — | — | US | claimed |
| EP-4512471-A2 | ACETYLCHOLINESTERASE INHIBITORS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | Attillaps Holdings (US) | 2025-02-26 | — | — | EP | claimed |
| US-20250042765-A1 | METHOD FOR TREATING A SURFACE CONTAMINATED WITH PSEUDOMONAS AERUGINOSA | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2025-02-06 | — | — | US | claimed |
| EP-4489858-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | claimed |
| US-12157677-B2 | Method for treating a biologically contaminated surface | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2024-12-03 | — | — | US | claimed |
| EP-4088724-B1 | ACETYLCHOLINESTERASE INHIBITORS FOR THE ORAL TREATMENT OF DERMATOLOGICAL CONDITIONS | ATTILLAPS HOLDINGS (US) | 2024-10-23 | — | — | EP | claimed |
| US-20240325324-A1 | COMPOSITIONS AND METHODS FOR TREATING DRY EYE | Genetic Disease Investigators, LLC | 2024-10-03 | — | — | US | claimed |
| US-20240018011-A1 | METHOD FOR TREATING A BIOLOGICALLY CONTAMINATED SURFACE | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2024-01-18 | — | — | US | claimed |
| US-11446241-B2 | Treatment of ophthalmological conditions with acetylcholinesterase inhibitors | ATTILLAPS HOLDINGS INC. (US) | 2022-09-20 | — | — | US | claimed |
| US-20220287313-A1 | USE OF DRIED CHICORY ROOT TO PROTECT POULTRY AND LIVESTOCK AGAINST ECTOPARASITES OR AS INSECT REPELLANT | COSUCRA GROUPE WARCOING S.A. (BE) | 2022-09-15 | — | — | US | claimed |
| EP-4048720-A1 | MULTILAYER DISSOLVABLE SOLID ARTICLE CONTAINING COATING COMPOSITION AND PROCESS FOR MAKING THE SAME | The Procter & Gamble Company (US) | 2022-08-31 | — | — | EP | claimed |
| EP-4031182-A1 | ENDOCANNABINOID MIMETIC AND ANTI-INFLAMMATORY COMPOUND CONTAINING COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | Pharma Cosmetix Research, LLC (US) | 2022-07-27 | — | — | EP | claimed |
| EP-3157534-B1 | ACETYLCHOLINESTERASE INHIBITORS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | ATTILLAPS HOLDINGS (US) | 2022-07-06 | — | — | EP | claimed |
| US-20220202739-A1 | ENDOCANNABINOID MIMETIC AND ANTI-INFLAMMATORY COMPOUND CONTAINING COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | PHARMA COSMETIX RES LLC (US) | 2022-06-30 | — | — | US | claimed |
| US-20220107305-A1 | Companion Diagnostics for NSAIDS and Donepezil for Treating Specific Subpopulations of Patients Suffering from Alzheimer's Disease | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH | 2022-04-07 | — | — | US | claimed |
| US-20220096420-A1 | Acetylcholinesterase Inhibitors for Treatment of Dermatological Conditions | ATTILLAPS HOLDINGS | 2022-03-31 | — | — | US | claimed |
| EP-3965732-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING PRESBYOPIA AND METHODS FOR FABRICATING THEREOF | Harrow IP, LLC (US) | 2022-03-16 | — | — | EP | claimed |
| US-20220023368-A1 | COMPOSITION COMPRISING CHICORY ROOT AND PEA CELL WALL FIBER FOR TREATING BRACHYSPIRA INFECTIONS | COSUCRA GROUPE WARCOING S.A. (BE) | 2022-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11446241-B2 | Treatment of ophthalmological conditions with acetylcholinesterase inhibitors | ACHE, BCHE, PON1 | ALDH1A1 427/4885NPC1 4067/4885MAPT 2492/4885 |
| US-20220096420-A1 | Acetylcholinesterase Inhibitors for Treatment of Dermatological Conditions | ACHE, PON1, CYP17A1 | ALDH1A1 370/4885NPC1 2143/4885MAPT 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.